Global Immunoprotein Diagnostic Testing Market - 2023-2030

Global Immunoprotein Diagnostic Testing Market - 2023-2030

Global Immunoprotein Diagnostic Testing Market reached US$ 9.4 billion in 2022 and is expected to reach US$ 15.8 billion by 2030 growing with a CAGR of 6.9% during the forecast period 2023-2030.

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze specific proteins such as immunoglobulin and pre-albumin. With continuous technological development, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Conditions such as cardiovascular disease, cancer, diabetes, and respiratory disease were causes or contributing factors for most of the mortality cases among the population. Due to the rise in these chronic diseases, immunoprotein testing has increased for early diagnosis of chronic diseases. These provide a rapid result, which aids in treating the condition in no time.

Furthermore, technological advancements, the increasing prevalence of chronic diseases among the population, and growing awareness about early disease diagnosis are the factors that drive the market in the forthcoming period.

Dynamics

Rising Advancements in Diagnostic Testing

Advancements in immunodiagnostic testing make the diagnosis more accurate and reliable for the treatment of diseases such as rheumatoid arthritis, celiac disease, etc. For instance, according to MDPI Journals, in 2023, the combination of microfluidic technology and machine learning effectively achieved the high-throughput detection of multiple immune biomarkers in a rapid, sensitive, selective, accurate, and easy-to-implement manner to be exploited as an advanced point-of-care (POC) detection platform for immune biomarkers effectively applicable for the early-stage diagnosis of diseases.

In another report, Teengam et al. introduced a smartphone-based portable immunosensing device for the detection of HBV, and the limit of detection was about 0.17 µg/mL of HBsAg in the clinical samples. With the use of smartphones, this low-cost electrochemical immunosensor not only provides real-time results with high sensitivity and portability

Increasing Incidence of Autoimmune Diseases

Autoimmune diseases affect about one in ten individuals. Autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Their burden continues to increase over time, albeit at varying rates across individual conditions. The socio-economic, seasonal, and regional disparities observed among several autoimmune disorders implicate environmental factors in disease pathogenesis.

For instance, according to BMJ journals, in 2023, autoimmune diseases affect around 10% of the global population, with 13% of women and 7% of men involved. By 2040, an estimated 78.4 million (25.9%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis (BRFSS). During the last decades, the incidence of the major pediatric chronic autoimmune diseases has increased rapidly1. Type 1 Diabetes has had an estimated annual increase of incidence of 2.4% per year worldwide and 3–4% in Europe.

High Costs of Diagnostic Tests

The cost of diagnosis is skyrocketing every day as the demand for early disease diagnosis has increased post-pandemic. For instance, according to Scientific Electronic Library Online states that two-thirds of older Medicare beneficiaries had two or more chronic conditions. They accounted for 99% of health expenditures, but the reason for this is a more heightened risk of hospital complications that increase the costs. Between March and June 2022, the prices of IFAT and ELISA kits were provided by six private laboratories. The average final cost per sample for consumers was estimated at US$ 30.69 for IFAT and US$ 4.88 for ELISA. These are too high for low and middle-income countries to afford; hence, most people skip early diagnosis and get treated for an end-stage disease when it's too late.

Segment Analysis

The global immunoprotein diagnostic testing is segmented based on product type, test type, application, end-user and region.

The Enzyme-linked immunosorbent assay Segment Accounted for Approximately 35.7% of the Market Share

Enzyme-linked immunosorbent assay is expected to increase the market share as the accuracy has increased. A rise in product launches due to the demand for immunodiagnostic testing is observed. For instance, in July 2022 KSL Beutner Laboratories launched a first-to-market Indirect Immunofluorescence (IIF) serum blood test in the US that positively identifies laminin 332, an antigen associated with the chronic, debilitating autoimmune disease mucous membrane pemphigoid (MMP).

Furthermore, in August 2023, Thermo Fisher Scientific launched the EXENT Solution. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. EXENT-iQ, is an intelligent and intuitive workflow software, including data review.

Geographical Analysis

North America accounted for Approximately 39.3% of the Market Share in 2022

North America is dominating the global immunoprotein diagnostic testing market and accounting for the largest market share, owing to rising incidences of chronic diseases, and rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year.

By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. Accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

COVID-19 Impact Analysis

The global pandemic has changed narratives around human health, compelling the medical research industry to develop new medical technologies and drugs. This factor reflects the pandemic's positive impact on the growth of the global immunoprotein diagnostic market. The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global immunoprotein diagnostic testing market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity

Lower capital expenditure is ongoing as businesses slow on investments, held back by inflation concerns and weaker demand. With slower growth and heightened inflation, expanded markets appear to enter a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path pose a real risk of the world experiencing more critical supply chain pain and manufacturing disruptions hindering the market.

By Product Type
• Instruments and Kits
• Radioimmunoassay
• Immunoturbidity Assay
• Immunoprotein Electrophoresis
• Enzyme-linked immunosorbent assay
• Chemiluminescence Assay
• Fluorescence Assay
• Colorimetric Assay
• Others
• Reagents
• Others

By Test Type
• Immunoglobulin Diagnostic Tests
• C-Reactive Protein (CRP) Diagnostic Tests
• Complement System Proteins Diagnostic Tests
• Free Light Chain Diagnostic Tests
• Haptoglobin Diagnostic Tests
• Prealbumin Diagnostic Tests
• Others

By Application
• Autoimmune Disease Testing
• Infectious Disease Testing
• Oncology Testing
• Allergy Testing
• Toxicology Testing
• Others

By End Users
• Hospital and clinics
• Diagnostic laboratories
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In July 2023, Anbio’s AF-100S FIA Solution is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes. The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients
• In May 2022, Omega Quant launched an HbA1c Test with a sample collection kit that allows for testing at home. This simple, safe, convenient test measures the amount of sugar (glucose) in the blood.
• American Society of Tropical Medicine & Hygiene is conducting its 2023 annual meeting in Chicago, USA from October 18-22 where research Meets real-world experience. The meeting draws tropical medicine and global health professionals representing academia, foundations, government, not-for-profit organizations, non-governmental organizations, the private sector, the military, and private practice.

Competitive Landscape

The major global players in the immunoprotein diagnostic testing market include Abbott Laboratories, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, F. Hoffmann-La Roche Ag, Enzo Biochem, Inc, Siemens AG, Ortho Clinical Diagnostics, Diasorin S.P.A, and Abcam Plc among others.

Why Purchase the Report?
• To visualize the global immunoprotein diagnostic testing market based on product type, test type, application, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of immunoprotein diagnostic testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global immunoprotein diagnostic testing market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies